Status | Study |
Recruiting |
Study Name: Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases Condition: Prostatic Neoplasms, Castration-Resistant Date: 2016-06-14 Interventions: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Xofigo treatment will be performed according to the pr |
Suspended |
Study Name: Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2015-12-07 Interventions: Biological: JNJ-64041809 (Cohort 1A and 1B) |
Active, not recruiting |
Study Name: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2015-10-29 Interventions: Drug: JNJ 56021927 JNJ 5602192 |
Recruiting |
Study Name: Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany Condition: Prostatic Neoplasms, Castration-Resistant Date: 2015-05-19 Interventions: Drug: Radium-223-dichloride (Xofigo, BAY88-8223) according to Summary of Product Characteristics |
Recruiting |
Study Name: Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer Condition: Prostate Cancer Date: 2015-04-15 Interventions: Biological: Dendritic cell based cryoimmunotherapy |
Recruiting |
Study Name: Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases Condition: Castration-Resistant Prostatic Cancer Date: 2015-03-20 Interventions: Drug: Radium-223 dichloride, (Xofigo, BAY88-8223) Dosage and treatment duration according to the decisio |
Recruiting |
Study Name: Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer Condition: Metastatic Castration-Resistant Prostatic Cancer Date: 2014-09-30 Interventions: Drug: cabazitaxel Cabazitaxel |
Recruiting |
Study Name: BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) Condition: Prostatic Neoplasms, Castration-Resistant Date: 2014-07-29 Interventions: Drug: BI 836845 Drug: Enzalutamide |
Active, not recruiting |
Study Name: A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2014-06-11 Interventions: Drug: JNJ-56021927 Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single or |
Terminated |
Study Name: F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Condition: Castration-resistant Prostate Cancer Date: 2013-08-01 Interventions: Device: F-Choline-PET |